Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Abarelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist, which is used for prostate cancer treatment.
Description | Abarelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist, which is used for prostate cancer treatment. |
In vitro | Abarelix (30 and 300 µg/mL) causes significantly increased histamine release[1]. Abarelix demonstrates to promptly and substantially reduce follicle-stimulating hormone levels to lower than LHRH agonist. Abarelix is the first GnRH antagonist to be developed which can produce rapid and sustained decreases in testosterone to castrate levels without the need for co-administration of an antiandrogen, and with a very low complication rate in the short term[2]. Abarelix does not cause a surge in serum testosterone that can precipitate a flare phenomenon or worsening of disease, particularly dangerous for patients with metastatic, symptomatic disease, and produces medical castration more quickly[3]. |
Synonyms | PPI 149, 阿巴瑞克, R3827 |
Molecular Weight | 1416.06 |
Formula | C72H95ClN14O14 |
CAS No. | 183552-38-7 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 14.2 mg/mL (10.03 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Abarelix 183552-38-7 G蛋白偶联受体 GNRH Receptor GNRHR R 3827 R3827 GnRH Receptor PPI-149 Gonadotropin releasing hormone receptor PPI 149 PPI149 inhibit R-3827 Inhibitor inhibitor